Related Experiment Videos
Inflammatory myopathies: how to treat the difficult cases
1Centre for Neuromuscular and Neurological Disorders, and Department of Medicine, University of Western Australia, Nedlands, WA, Australia. flmast@cyllene.uwa.edu.au
Summary
Early introduction of second-line agents like methotrexate or azathioprine is crucial for inflammatory myopathy treatment. Intravenous immunoglobulin and newer immunosuppressants offer options for refractory cases, though inclusion body myositis treatment remains challenging.
Area of Science:
- Neurology
- Immunology
- Rheumatology
Background:
- Inflammatory myopathies require careful treatment strategies for optimal patient outcomes.
- Corticosteroid monotherapy can lead to adverse effects with prolonged use.
Purpose of the Study:
- To outline optimal treatment approaches for inflammatory myopathies.
- To guide the selection of first- and second-line therapies.
Main Methods:
- Review of current treatment guidelines and evidence for inflammatory myopathies.
- Discussion of various immunosuppressive agents and their roles.
Main Results:
- Early use of methotrexate or azathioprine is recommended over prolonged high-dose corticosteroids.
- Intravenous immunoglobulin is effective for active myositis, especially in dermatomyositis and immunodeficient patients.
- Cyclophosphamide, cyclosporine, mycophenolate mofetil, and tacrolimus are options for resistant cases.
Conclusions:
- A strategic, multi-agent approach is essential for managing inflammatory myopathies.
- Inclusion body myositis treatment remains difficult, but trials with prednisolone and methotrexate may benefit selected patients.